News

The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat

The intellectual property related to the panel will also be obtained by the company. Upon execution of the license, Genmab will make a one-time $4m licensing payment to

The recommendation for this combination follows a review by the NHS and Care Excellence (NICE). The combination therapy is indicated for patients with non-small cell lung cancer (NSCLC)

Perrigo will acquire rights to the nicotine replacement therapies of both GSK and Novartis, NiQuitin and Nicotinell. Novartis’s cold sore management products in the EEA and cold and

Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government’s repository of critical medical supplies for biowarfare preparedness. Anthim has been developed under

Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology.

The trial met its primary endpoint of time from randomization to first clinical fracture (HR=0.5, 95 percent CI 0.39-0.65, p<0.0001). The observed 50 percent reduction in fractures between

The drug development and license agreement between Transposagen and Janssen, which was announced in November of 2014, has been transferred to Poseida. The three-year drug development partnership and

Researchers from both the parties will initially focus on canine malignant melanoma, or skin cancer, and test Nuovo’s new anti-cancer peptide drug MMX for its ability to treat